SAGE — Sage Therapeutics Balance Sheet
0.000.00%
- $457.13m
- $33.28m
- $41.24m
- 31
- 20
- 39
- 19
Annual balance sheet for Sage Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,100 | 1,742 | 1,272 | 753 | 504 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 18.5 | 13.7 | 88.6 | 12.9 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,122 | 1,801 | 1,337 | 869 | 531 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 31.8 | 19.1 | 13.4 | 6.38 | 11.6 |
Other Long Term Assets | |||||
Total Assets | 2,159 | 1,825 | 1,356 | 882 | 547 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 67.2 | 85.2 | 99.3 | 82.7 | 71.6 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 86.9 | 96.3 | 104 | 82.7 | 82.1 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 2,072 | 1,729 | 1,253 | 800 | 465 |
Total Liabilities & Shareholders' Equity | 2,159 | 1,825 | 1,356 | 882 | 547 |
Total Common Shares Outstanding |